RÉSUMÉ
AIM: An analysis of bioinformatics and cell experiments was performed to verify the relationship between gasdermin D (GSDMD), an executive protein of pyroptosis, and Alzheimer's disease (AD). METHODS: The training set GSE33000 was utilized to identify differentially expressed genes (DEGs) in both the AD group and control group, as well as in the GSDMD protein high/low expression group. Subsequently, the weighted gene co-expression network analysis (WGCNA) and the least absolute shrinkage and selection operator (LASSO) regression analysis were conducted, followed by the selection of the key genes for the subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The association between GSDMD and AD was assessed and confirmed in the training set GSE33000, as well as in the validation sets GSE5281 and GSE48350. Immunofluorescence (IF) was employed to detect the myelin basic protein (MBP), a distinctive protein found in the rat oligodendrocytes (OLN-93 cells). A range of concentrations (1-15 µmol/L) of ß-amyloid 1-42 (Aß1-42) were exposed to the cells, and the subsequent observations were made regarding cell morphology. Additionally, the assessments were conducted to evaluate the cell viability, the lactate dehydrogenase (LDH) release, the cell membrane permeability, and the GSDMD protein expression. RESULTS: A total of 7,492 DEGs were screened using GSE33000. Subsequently, WGCNA analysis identified 19 genes that exhibited the strongest correlation with clinical traits in AD. Additionally, LASSO regression analysis identified 13 key genes, including GSDMD, AFF1, and ATOH8. Furthermore, the investigation revealed that the key genes were associated with cellular inflammation based on GO and KEGG analyses. Moreover, the area under the curve (AUC) values for the key genes in the training and validation sets were determined to be 0.95 and 0.70, respectively. Significantly, GSDMD demonstrated elevated levels of expression in AD across both datasets. The positivity of MBP expression in cells exceeded 95%. As the concentration of Aß1-42 action gradually escalated, the detrimental effects on cells progressively intensified, resulting in a gradual decline in cell survival rate, accompanied by an increase in lactate dehydrogenase release, cell membrane permeability, and GSDMD protein expression. CONCLUSION: The association between GSDMD and AD has been observed, and it has been found that Aß1-42 can induce a significant upregulation of GSDMD in OLN-93 cells. This suggests that Aß1-42 has the potential to induce cellular pyroptosis and can serve as a valuable cellular pyroptosis model for the study of AD.
Sujet(s)
Maladie d'Alzheimer , Protéines de liaison aux phosphates , Pyroptose , Maladie d'Alzheimer/métabolisme , Pyroptose/effets des médicaments et des substances chimiques , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Humains , Animaux , Rats , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Peptides bêta-amyloïdes/métabolisme , Biologie informatique , Fragments peptidiques/métabolisme , GasderminesRÉSUMÉ
During meiosis, nucleoprotein filaments of the strand exchange proteins RAD51 and DMC1 are crucial for repairing SPO11-generated DNA double-strand breaks (DSBs) by homologous recombination (HR). A balanced activity of positive and negative RAD51/DMC1 regulators ensures proper recombination. Fidgetin-like 1 (FIGNL1) was previously shown to negatively regulate RAD51 in human cells. However, FIGNL1's role during meiotic recombination in mammals remains unknown. Here, we decipher the meiotic functions of FIGNL1 and FIGNL1 Interacting Regulator of Recombination and Mitosis (FIRRM) using male germline-specific conditional knock-out (cKO) mouse models. Both FIGNL1 and FIRRM are required for completing meiotic prophase in mouse spermatocytes. Despite efficient recruitment of DMC1 on ssDNA at meiotic DSB hotspots, the formation of late recombination intermediates is defective in Firrm cKO and Fignl1 cKO spermatocytes. Moreover, the FIGNL1-FIRRM complex limits RAD51 and DMC1 accumulation on intact chromatin, independently from the formation of SPO11-catalyzed DSBs. Purified human FIGNL1ΔN alters the RAD51/DMC1 nucleoprotein filament structure and inhibits strand invasion in vitro. Thus, this complex might regulate RAD51 and DMC1 association at sites of meiotic DSBs to promote proficient strand invasion and processing of recombination intermediates.
Sujet(s)
Protéines du cycle cellulaire , Cassures double-brin de l'ADN , Protéines de liaison à l'ADN , Méiose , Souris knockout , Rad51 Recombinase , Spermatocytes , Rad51 Recombinase/métabolisme , Rad51 Recombinase/génétique , Animaux , Mâle , Méiose/génétique , Protéines du cycle cellulaire/métabolisme , Protéines du cycle cellulaire/génétique , Humains , Souris , Spermatocytes/métabolisme , Protéines de liaison à l'ADN/métabolisme , Protéines de liaison à l'ADN/génétique , Recombinaison homologue , Protéines nucléaires/métabolisme , Protéines nucléaires/génétique , Altération de l'ADN , Endodeoxyribonucleases/métabolisme , Endodeoxyribonucleases/génétique , Chromatine/métabolisme , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétiqueRÉSUMÉ
Pyroptosis is an inflammatory programed cell death process that plays a crucial role in cancer therapeutic, while Gasdermin-D is a critical effector protein for pyroptosis execution. This review discusses the intricate interactions between Gasdermin-D and some non-coding RNAs (lncRNA, miRNA, siRNA) and their potential application in the regulation of pyroptosis as an anticancer therapy. Correspondingly, these ncRNAs significantly implicate in Gasdermin-D expression and function regarding the pyroptosis pathway. Functioning as competing endogenous RNAs (ceRNAs), these ncRNAs might regulate Gasdermin-D at the molecular level, underlying fatal cell death caused by cancer and tumor propagation. Therefore, these interactions appeal to therapeutics, offering new avenues for cancer treatment. It address this research gap by discussing the possible roles of ncRNAs as mediators of gasdermin-D regulation. It suggest therapeutic strategies based on the current research findings to ensure the interchange between the ideal pyroptosis and cancer cell death.
Sujet(s)
Protéines et peptides de signalisation intracellulaire , Tumeurs , Protéines de liaison aux phosphates , Pyroptose , ARN non traduit , Pyroptose/physiologie , Humains , Tumeurs/anatomopathologie , Tumeurs/génétique , Tumeurs/métabolisme , Tumeurs/thérapie , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , ARN non traduit/génétique , ARN non traduit/métabolisme , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Animaux , Régulation de l'expression des gènes tumoraux , GasderminesRÉSUMÉ
Immune checkpoint inhibitor (ICI)-induced myocarditis involves intensive immune/inflammation activation; however, its molecular basis is unclear. Here, we show that gasdermin-E (GSDME), a gasdermin family member, drives ICI-induced myocarditis. Pyroptosis mediated by GSDME, but not the canonical GSDMD, is activated in myocardial tissue of mice and cancer patients with ICI-induced myocarditis. Deficiency of GSDME in male mice alleviates ICI-induced cardiac infiltration of T cells, macrophages, and monocytes, as well as mitochondrial damage and inflammation. Restoration of GSDME expression specifically in cardiomyocytes, rather than myeloid cells, in GSDME-deficient mice reproduces ICI-induced myocarditis. Mechanistically, quantitative proteomics reveal that GSDME-dependent pyroptosis promotes cell death and mitochondrial DNA release, which in turn activates cGAS-STING signaling, triggering a robust interferon response and myocardial immune/inflammation activation. Pharmacological blockade of GSDME attenuates ICI-induced myocarditis and improves long-term survival in mice. Our findings may advance the understanding of ICI-induced myocarditis and suggest that targeting the GSDME-cGAS-STING-interferon axis may help prevent and manage ICI-associated myocarditis.
Sujet(s)
Inhibiteurs de points de contrôle immunitaires , Protéines membranaires , Myocardite , Nucleotidyltransferases , Pyroptose , Animaux , Myocardite/immunologie , Myocardite/anatomopathologie , Myocardite/induit chimiquement , Myocardite/métabolisme , Protéines membranaires/métabolisme , Protéines membranaires/génétique , Inhibiteurs de points de contrôle immunitaires/pharmacologie , Inhibiteurs de points de contrôle immunitaires/effets indésirables , Souris , Mâle , Humains , Nucleotidyltransferases/métabolisme , Nucleotidyltransferases/génétique , Transduction du signal , Souris de lignée C57BL , Souris knockout , ADN mitochondrial/métabolisme , ADN mitochondrial/génétique , Femelle , Myocytes cardiaques/métabolisme , Myocytes cardiaques/anatomopathologie , Myocytes cardiaques/effets des médicaments et des substances chimiques , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , GasderminesRÉSUMÉ
Diabetic cardiomyopathy (DCM) is a chronic disease caused by diabetes mellitus, which is recognized as a worldwide challenging disease. This study aimed to investigate the role and the potential mechanism of knocking down the NACHT-, LRR- and PYD domains-containing protein 3 (NLRP3), an inflammasome associated with onset and progression of various diseases, on high glucose or diabetes -induced cardiac cells pyroptosis and ferroptosis, two regulated non-necrosis cell death modalities discovered recent years. In the present study, both in vivo and in vitro studies were conducted simultaneously. Diabetic rats were induced by 55 mg/kg intraperitoneal injection of streptozotocin (STZ). Following the intraperitoneal injection of MCC950 (10 mg/kg), On the other hand, the DCM model in H9C2 cardiac cells was simulated with 35 mmol/L glucose and a short hairpin RNA vector of NLRP3 were transfected to cells. The results showed that in vivo study, myocardial fibers were loosely arranged and showed inflammatory cell infiltration, mitochondrial cristae were broken and the GSDMD-NT expression was found notably increased in the DM group, while the protein expressions of xCT and GPX4 was significantly decreased, both of which were reversed by MCC950. High glucose reduced the cell viability and ATP level in vitro, accompanied by an increase in LDH release. All of the above indicators were reversed after NLRP3 knockdown compared with the HG treated alone. Moreover, the protein expressions of pyroptosis- and ferroptosis-related fators were significantly decreased or increased, consistent with the results shown by immunofluorescence. Furthermore, the protective effects of NLRP3 knockdown against HG were reversed following the mtROS agonist rotenone (ROT) treatment. In conclusion, inhibition of NLRP3 suppressed DM-induced myocardial injury. Promotion of mitochondrial ROS abolished the protective effect of knockdown NLRP3, and induced the happening of pyroptosis and ferroptosis. These findings may present a novel therapeutic underlying mechanism for clinical diabetes-induced myocardial injury treatment.
Sujet(s)
Diabète expérimental , Cardiomyopathies diabétiques , Ferroptose , Techniques de knock-down de gènes , Myocytes cardiaques , Protéine-3 de la famille des NLR contenant un domaine pyrine , Pyroptose , Animaux , Ferroptose/effets des médicaments et des substances chimiques , Protéine-3 de la famille des NLR contenant un domaine pyrine/métabolisme , Protéine-3 de la famille des NLR contenant un domaine pyrine/génétique , Cardiomyopathies diabétiques/métabolisme , Cardiomyopathies diabétiques/génétique , Cardiomyopathies diabétiques/anatomopathologie , Cardiomyopathies diabétiques/étiologie , Cardiomyopathies diabétiques/physiopathologie , Myocytes cardiaques/métabolisme , Myocytes cardiaques/anatomopathologie , Mâle , Diabète expérimental/complications , Diabète expérimental/métabolisme , Lignée cellulaire , Rat Sprague-Dawley , Rats , Transduction du signal , Espèces réactives de l'oxygène/métabolisme , Inflammasomes/métabolisme , Sulfonamides/pharmacologie , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , GasderminesRÉSUMÉ
Gasdermin D (GSDMD)-mediated pyroptotic cell death drives inflammatory cytokine release and downstream immune responses upon inflammasome activation, which play important roles in host defense and inflammatory disorders. Upon activation by proteases, the GSDMD N-terminal domain (NTD) undergoes oligomerization and membrane translocation in the presence of lipids to assemble pores. Despite intensive studies, the molecular events underlying the transition of GSDMD from an autoinhibited soluble form to an oligomeric pore form inserted into the membrane remain incompletely understood. Previous work characterized S-palmitoylation for gasdermins from bacteria, fungi, invertebrates, as well as mammalian gasdermin E (GSDME). Here, we report that a conserved residue Cys191 in human GSDMD was S-palmitoylated, which promoted GSDMD-mediated pyroptosis and cytokine release. Mutation of Cys191 or treatment with palmitoyltransferase inhibitors cyano-myracrylamide (CMA) or 2-bromopalmitate (2BP) suppressed GSDMD palmitoylation, its localization to the membrane and dampened pyroptosis or IL-1ß secretion. Furthermore, Gsdmd-dependent inflammatory responses were alleviated by inhibition of palmitoylation in vivo. By contrast, coexpression of GSDMD with palmitoyltransferases enhanced pyroptotic cell death, while introduction of exogenous palmitoylation sequences fully restored pyroptotic activities to the C191A mutant, suggesting that palmitoylation-mediated membrane localization may be distinct from other molecular events such as GSDMD conformational change during pore assembly. Collectively, our study suggests that S-palmitoylation may be a shared regulatory mechanism for GSDMD and other gasdermins, which points to potential avenues for therapeutically targeting S-palmitoylation of gasdermins in inflammatory disorders.
Sujet(s)
Cystéine , Protéines et peptides de signalisation intracellulaire , Lipoylation , Protéines de liaison aux phosphates , Pyroptose , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Humains , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Cystéine/métabolisme , Animaux , Souris , Cytokines/métabolisme , Cellules HEK293 , Inflammasomes/métabolisme , GasderminesRÉSUMÉ
Nod-like receptor family pyrin-containing protein 3 (NLRP3) inflammasome plays a pathologic role in metabolic dysfunction-associated steatohepatitis (MASH), but the molecular mechanism regulating the NLRP3 inflammasome activation in hepatocellular lipotoxicity remains largely unknown. Bromodomain-containing protein 4 (BRD4) has emerged as a key epigenetic reader of acetylated lysine residues in enhancer regions that control the transcription of key genes. The aim of this study is to investigate if and how BRD4 regulated the NLRP3 inflammasome activation and pyroptosis in MASH. Using the AML12 and primary mouse hepatocytes stimulated by palmitic acid (PA) as an in vitro model of hepatocellular lipotoxicity, we found that targeting BRD4 by genetic knockdown or a selective BRD4 inhibitor MS417 protected against hepatosteatosis; and this protective effect was attributed to inhibiting the activation of NLRP3 inflammasome and reducing the expression of Caspase-1, gasdermin D (GSDMD), interleukin (IL)-1ß and IL-6. Moreover, BRD4 inhibition limited the voltage-dependent anion channel-1 (VDAC1) expression and oligomerization in PA-treated AML12 hepatocytes, thereby suppressing the NLRP3 inflammasome activation. Additionally, the expression of BRD4 enhanced in MASH livers of humans. Mechanistically, BRD4 was upregulated during hepatocellular lipotoxicity that in turn modulated the active epigenetic mark H3K27ac at the promoter regions of the Vdac and Gsdmd genes, thereby enhancing the expression of VDAC and GSDMD. Altogether, our data provide novel insights into epigenetic mechanisms underlying BRD4 activating the NLRP3 inflammasome and promoting GSDMD-mediated pyroptosis in hepatocellular lipotoxicity. Thus, BRD4 might serve as a novel therapeutic target for the treatment of MASH.
Sujet(s)
Hépatocytes , Inflammasomes , Souris de lignée C57BL , Protéine-3 de la famille des NLR contenant un domaine pyrine , Protéines de liaison aux phosphates , Pyroptose , Facteurs de transcription , Animaux , Humains , Mâle , Souris , Protéines contenant un bromodomaine , Protéines du cycle cellulaire , Stéatose hépatique/métabolisme , Stéatose hépatique/anatomopathologie , Furanes , Gasdermines , Hépatocytes/métabolisme , Hépatocytes/effets des médicaments et des substances chimiques , Hépatocytes/anatomopathologie , Composés hétérocycliques avec 4 noyaux ou plus/pharmacologie , Indènes/pharmacologie , Inflammasomes/métabolisme , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Protéine-3 de la famille des NLR contenant un domaine pyrine/métabolisme , Protéines nucléaires , Acide palmitique/pharmacologie , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Pyroptose/effets des médicaments et des substances chimiques , Sulfonamides/pharmacologie , Facteurs de transcription/métabolisme , Facteurs de transcription/génétiqueRÉSUMÉ
Psoraleae Fructus (PF, Psoralea corylifolia L.), a traditional medicine with a long history of application, is widely used clinically for the treatment of various diseases. However, the reports of PF-related adverse reactions, such as hepatotoxicity, phototoxic dermatitis, and allergy, are increasing year by year, with liver injury being the mostly common. Our previous studies have demonstrated that PF and its preparations can cause liver injury in lipopolysaccharide (LPS)-mediated susceptibility mouse model, but the mechanism of PF-related liver injury is unclear. In this study, we showed that PF and bavachinin, a major component of PF, can directly induce the expression of caspase-1 and interleukin-1ß (IL-1ß), indicating that PF and bavachinin can directly triggered the activation of inflammasome. Furthermore, pretreatment with NLR family pyrin domain-containing 3 (NLRP3), NLR family CARD domain containing 4 (NLRC4) or absent in melanoma 2 (AIM2) inflammasome inhibitors, containing MCC950, ODN TTAGGG (ODN) and carnosol, all significantly reversed bavachinin-induced inflammasome activation. Mechanistically, bavachinin dose-dependently promote Gasdermin D (GSDMD) post-shear activation and then induce mitochondrial reactive oxygen species (mtROS) production and this effect is markedly inhibited by pretreatment with N-Acetylcysteine amide (NAC). In addition, combination treatment of LPS and bavachinin significantly induced liver injury in mice, but not LPS or bavachinin alone, and transcriptome analysis further validated these results. Thus, PF and bavachinin can induce the activation of inflammasome by promoting GSDMD cleavage and cause hepatotoxicity in mice. Therefore, PF, bavachinin, and PF-related preparations should be avoided in patients with inflammasome activation-associated diseases.
Sujet(s)
Inflammasomes , Protéines de liaison aux phosphates , Psoralea , Pyroptose , Animaux , Pyroptose/effets des médicaments et des substances chimiques , Souris , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Psoralea/composition chimique , Inflammasomes/métabolisme , Protéines et peptides de signalisation intracellulaire/métabolisme , Mâle , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/anatomopathologie , Souris de lignée C57BL , Lipopolysaccharides/toxicité , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/anatomopathologie , Flavonoïdes/pharmacologie , Protéine-3 de la famille des NLR contenant un domaine pyrine/métabolisme , Caspase-1/métabolisme , Interleukine-1 bêta/métabolisme , GasderminesRÉSUMÉ
Aim: Understanding molecular mechanisms of Helicobacter pylori (H. pylori)-induced inflammation is important for developing new therapeutic strategies for gastrointestinal diseases.Materials & methods: We designed an H. pylori-neutrophil infection model and explored the effects of H. pylori infection on neutrophils.Results: H. pylori infected neutrophils showed a low level of apoptosis. H. pylori stimulation activated the NACHT/LRR/PYD domain-containing protein 3 (NLRP3)-gasdermin-D (GSDMD) pathway for interleukin (IL)-1ß secretion. However, IL-1ß secretion was not completely dependent on GSDMD, as inhibition of autophagy significantly reduced IL-1ß release, and autophagy-related molecules were significantly upregulated in H. pylori-infected neutrophils.Conclusion: Therefore, H. pylori infection inhibits neutrophils apoptosis and induces IL-1ß secretion through autophagy. These findings may be utilized to formulate therapeutic strategies against H. pylori mediated chronic gastritis.
[Box: see text].
Sujet(s)
Apoptose , Autophagie , Infections à Helicobacter , Helicobacter pylori , Inflammation , Interleukine-1 bêta , Granulocytes neutrophiles , Granulocytes neutrophiles/immunologie , Granulocytes neutrophiles/métabolisme , Infections à Helicobacter/microbiologie , Infections à Helicobacter/immunologie , Infections à Helicobacter/anatomopathologie , Interleukine-1 bêta/métabolisme , Humains , Inflammation/métabolisme , Protéine-3 de la famille des NLR contenant un domaine pyrine/métabolisme , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Gastrite/microbiologie , Gastrite/anatomopathologie , Gastrite/immunologie , AnimauxSujet(s)
Barrière hémato-encéphalique , Encéphalopathies , Humains , Barrière hémato-encéphalique/métabolisme , Encéphalopathies/traitement médicamenteux , Encéphalopathies/métabolisme , Animaux , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Encéphale/métabolisme , Encéphale/effets des médicaments et des substances chimiques , Cellules endothéliales/effets des médicaments et des substances chimiques , Cellules endothéliales/métabolismeRÉSUMÉ
Gasdermin D (GSDMD) is emerging as an important player in autoimmune diseases, but its exact role in lupus nephritis (LN) remains controversial. Here, we identified markedly elevated GSDMD in human and mouse LN kidneys, predominantly in CD11b+ myeloid cells. Global or myeloid-conditional deletion of GSDMD was shown to exacerbate systemic autoimmunity and renal injury in lupus mice with both chronic graft-versus-host (cGVH) disease and nephrotoxic serum (NTS) nephritis. Interestingly, RNA sequencing and flow cytometry revealed that myeloid GSDMD deficiency enhanced granulopoiesis at the hematopoietic sites in LN mice, exhibiting remarkable enrichment of neutrophil-related genes, significant increases in total and immature neutrophils as well as granulocyte/macrophage progenitors (GMPs). GSDMD-deficient GMPs and all-trans-retinoic acid (ATRA)-stimulated human promyelocytes NB4 were further demonstrated to possess enhanced clonogenic and differentiation abilities compared with controls. Mechanistically, GSDMD knockdown promoted self-renewal and granulocyte differentiation by restricting calcium influx, contributing to granulopoiesis. Functionally, GSDMD deficiency led to increased pathogenic neutrophil extracellular traps (NETs) in lupus peripheral blood and bone marrow-derived neutrophils. Taken together, our data establish that GSDMD deletion accelerates LN development by promoting granulopoiesis in a calcium influx-regulated manner, unraveling its unrecognized critical role in LN pathogenesis.
Sujet(s)
Calcium , Glomérulonéphrite lupique , Protéines de liaison aux phosphates , Glomérulonéphrite lupique/anatomopathologie , Glomérulonéphrite lupique/métabolisme , Glomérulonéphrite lupique/génétique , Animaux , Humains , Souris , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Protéines de liaison aux phosphates/déficit , Calcium/métabolisme , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Protéines et peptides de signalisation intracellulaire/déficit , Granulocytes neutrophiles/métabolisme , Granulocytes/métabolisme , Cellules myéloïdes/métabolisme , Souris de lignée C57BL , Femelle , Pièges extracellulaires/métabolisme , Différenciation cellulaire , GasderminesRÉSUMÉ
Rabies virus (RABV) is a neurotropic virus that causes fatal neurological disease, raising serious public health issues and attracting extensive attention in society. To elucidate the molecular mechanism of RABV-induced neuronal damage, we used hematoxylin-eosin staining, transmission electron microscopy, transcriptomics analysis, and immune response factor testing to investigate RABV-infected neurons. We successfully isolated the neurons from murine brains. The specificity of the isolated neurons was identified by a monoclonal antibody, and the viability of the neurons was 83.53-95.0%. We confirmed that RABV infection induced serious damage to the neurons according to histochemistry and transmission electron microscope (TEM) scanning. In addition, the transcriptomics analysis suggested that multiple genes related to the pyroptosis pathway were significantly upregulated, including gasdermin D (Gsdmd), Nlrp3, caspase-1, and IL-1ß, as well as the chemokine genes Ccl2, Ccl3, Ccl4, Ccl5, Ccl7, Ccl12, and Cxcl10. We next verified this finding in the brains of mice infected with the rRC-HL, GX074, and challenge virus standard strain-24 (CVS-24) strains of RABV. Importantly, we found that the expression level of the Gsdmd protein was significantly upregulated in the neurons infected with different RABV strains and ranged from 691.1 to 5764.96 pg/mL, while the basal level of mock-infected neurons was less than 100 pg/mL. Taken together, our findings suggest that Gsdmd-induced pyroptosis is involved in the neuron damage caused by RABV infection.
Sujet(s)
Neurones , Protéines de liaison aux phosphates , Pyroptose , Virus de la rage , Rage (maladie) , Animaux , Neurones/virologie , Neurones/métabolisme , Neurones/anatomopathologie , Virus de la rage/pathogénicité , Virus de la rage/physiologie , Rage (maladie)/virologie , Rage (maladie)/anatomopathologie , Rage (maladie)/métabolisme , Souris , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Encéphale/virologie , Encéphale/anatomopathologie , Encéphale/métabolisme , GasderminesRÉSUMÉ
Three recent publications by Du et al.,1 Balasubramanian et al.,2 and Zhang et al.3 identified palmitoylation on cysteine 191/192 in gasdermin D as a key determinant of gasdermin D membrane translocation and oligomerization, ensuring efficient plasma membrane permeabilization during pyroptosis.
Sujet(s)
Lipoylation , Protéines de liaison aux phosphates , Pyroptose , Humains , Animaux , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Membrane cellulaire/métabolisme , Cystéine/métabolisme , Transport des protéines , GasderminesRÉSUMÉ
Emerging evidence demonstrates that pyroptosis has been implicated in the pathogenesis of asthma. Gasdermin D (GSDMD) is the pyroptosis executioner. The mechanism of GSDMD in asthma remains unclear. The aim of this study was to elucidate the potential role of GSDMD in asthmatic airway inflammation and remodeling. Immunofluorescence staining was conducted on airway epithelial tissues obtained from both asthma patients and healthy controls (HCs) to evaluate the expression level of N-GSDMD. ELISA was used to measure concentrations of cytokines (IL-1ß, IL-18, IL-17A, and IL-10) in serum samples collected from asthma patients and healthy individuals. We demonstrated that N-GSDMD, IL-18, and IL-1ß were significantly increased in samples with mild asthma compared with those from the controls. Then, wild type and Gsdmd-knockout (Gsdmd-/-) mice were used to establish asthma model. We performed histopathological staining, ELISA, and flow cytometry to explore the function of GSDMD in allergic airway inflammation and tissue remodeling in vivo. We observed that the expression of N-GSDMD, IL-18, and IL-1ß was enhanced in OVA-induced asthma mouse model. Gsdmd knockout resulted in attenuated IL-18, and IL-1ß production in both bronchoalveolar lavage fluid (BALF) and lung tissue in asthmatic mice. In addition, Gsdmd-/- mice exhibit a significant reduction in airway inflammation and remodeling, which might be associated with reduced Th17 inflammatory response and M2 polarization of macrophages. Further, we found that GSDMD knockout may improve asthmatic airway inflammation and remodeling through regulating macrophage adhesion, migration, and macrophage M2 polarization by targeting Notch signaling pathway. These findings demonstrate that GSDMD deficiency profoundly alleviates allergic inflammation and tissue remodeling. Therefore, GSDMD may serve as a potential therapeutic target against asthma.
Sujet(s)
Asthme , Modèles animaux de maladie humaine , Protéines et peptides de signalisation intracellulaire , Souris knockout , Ovalbumine , Protéines de liaison aux phosphates , Animaux , Asthme/génétique , Asthme/anatomopathologie , Asthme/métabolisme , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Souris , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Humains , Remodelage des voies aériennes , Femelle , Inflammation/anatomopathologie , Inflammation/métabolisme , Inflammation/génétique , Souris de lignée C57BL , Mâle , Cytokines/métabolisme , Pyroptose , Poumon/anatomopathologie , Poumon/métabolisme , GasderminesRÉSUMÉ
BACKGROUND: Senescence is a cellular aging-related process triggered by different stresses and characterized by the secretion of various inflammatory factors referred to as senescence-associated secretory phenotype (SASP), some of which are produced by the NLRP3 inflammasome. Here, we present evidence that the NLRP1 inflammasome is a DNA damage sensor and a key mediator of senescence. METHODS: Senescence was induced in fibroblasts in vitro and in mice. Cellular senescence was assessed by Western blot analysis of several proteins, including p16, p21, p53, and SASP factors, released in the culture media or serum. Inflammasome components, including NLRP1, NLRP3 and GSDMD were knocked out or silenced using siRNAs. RESULTS: In vitro and in vivo results suggest that the NLRP1 inflammasome promotes senescence by regulating the expression of p16, p21, p53, and SASP factors in a Gasdermin D (GSDMD)-dependent manner. Mechanistically, the NLRP1 inflammasome is activated in response to genomic damage detected by the cytosolic DNA sensor cGMP-AMP (cGAMP) synthase (cGAS). CONCLUSION: Our findings show that NLRP1 is a cGAS-dependent DNA damage sensor during senescence and a mediator of SASP release through GSDMD. This study advances the knowledge on the biology of the NLRP1 inflammasome and highlights this pathway as a potential pharmcological target to modulate senescence.
Sujet(s)
Protéines adaptatrices de la transduction du signal , Vieillissement de la cellule , Altération de l'ADN , Fibroblastes , Inflammasomes , Protéines et peptides de signalisation intracellulaire , Souris de lignée C57BL , Protéines de liaison aux phosphates , Phénotype sécrétoire associé à la sénescence , Animaux , Inflammasomes/métabolisme , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Protéines adaptatrices de la transduction du signal/métabolisme , Protéines adaptatrices de la transduction du signal/génétique , Fibroblastes/métabolisme , Protéines régulatrices de l'apoptose/métabolisme , Protéines régulatrices de l'apoptose/génétique , Protéines NLR/métabolisme , Protéines NLR/génétique , Nucleotidyltransferases/métabolisme , Nucleotidyltransferases/génétique , Souris , Protéine p53 suppresseur de tumeur/métabolisme , Protéine p53 suppresseur de tumeur/génétique , Cellules cultivées , Souris knockout , Humains , Protéine-3 de la famille des NLR contenant un domaine pyrine , GasderminesRÉSUMÉ
Activation of Gasdermin D (GSDMD) results in its cleavage, oligomerization, and subsequent formation of plasma membrane pores, leading to a form of inflammatory cell death denoted as pyroptosis. The roles of GSDMD in inflammation and immune responses to infection are well documented. However, whether GSDMD also plays a role in sporadic cancer development, especially that in the gut epithelium, remains unknown. Here, we show that GSDMD is activated in colorectal tumors of both human and mouse origins. Ablation of GSDMD in a mouse model of sporadic colorectal cancer resulted in reduced tumor formation in the colon and rectum, suggesting a tumor-promoting role of the protein in the gut. Both antibiotic-mediated depletion of gut microbiota and pharmacological inhibition of NLRP3 inflammasome reduced the activation of GSDMD. Loss of GSDMD resulted in reduced infiltration of immature myeloid cells, and increased numbers of macrophages in colorectal tumors. Activation of GSDMD is also accompanied by the aggregation of the endosomal sorting complex required for transport (ESCRT) membrane repair proteins on the membrane of colorectal tumor cells, suggesting that active membrane repairment may prevent pyroptosis induced by the formation of GSDMD pore in tumor cells. Our results show that gut microbiota/NLRP3-mediated activation of GSDMD promotes the development of colorectal tumors, and supports the use of NLRP3 inhibitors to treat colon cancer.
Sujet(s)
Tumeurs colorectales , Microbiome gastro-intestinal , Protéines et peptides de signalisation intracellulaire , Protéines de liaison aux phosphates , Animaux , Souris , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Humains , Tumeurs colorectales/microbiologie , Tumeurs colorectales/anatomopathologie , Tumeurs colorectales/métabolisme , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Carcinogenèse/métabolisme , Inflammasomes/métabolisme , Pyroptose , Modèles animaux de maladie humaine , GasderminesRÉSUMÉ
Ulcerative colitis (UC) is a major inflammatory bowel disease (IBD) characterized by intestinal epithelium damage. Recently, Lipocalin-2 (LCN2) has been identified as a potential fecal biomarker for patients with UC. However, further investigation is required to explore its pro-inflammatory role in UC and the underlying mechanism. The biological analysis revealed that Lcn2 serves as a putative signature gene in the colon mucosa of patients with UC and its association with the capsase/pyroptosis signaling pathway in UC. In wild-type mice with DSS-induced colitis, LCN2 overexpression in colon mucosa via in vivo administration of Lcn2 overexpression plasmid resulted in exacerbation of colitis symptoms and epithelium damage, as well as increased expression levels of pyroptosis markers (cleaved caspase1, GSDMD, IL-1ß, HMGB1 and IL-18). Additionally, we observed downregulation in the expression levels of pyroptosis markers following in vivo silencing of LCN2. However, the pro-inflammatory effect of LCN2 overexpression was effectively restrained in GSDMD-KO mice. Moreover, single-cell RNA-sequencing analysis revealed that Lcn2 was predominantly expressed in the intestinal epithelial cells (IECs) within the colon mucosa of patients with UC. We found that LCN2 effectively regulated pyroptosis events by modulating the NF-κB/NLRP3/GSDMD signaling axis in NCM460 cells stimulated by LPS and ATP. These findings demonstrate the pro-inflammatory role of LCN2 in colon epithelium and provide a potential target for inhibiting pyroptosis in UC.
Sujet(s)
Muqueuse intestinale , Lipocaline-2 , Facteur de transcription NF-kappa B , Protéine-3 de la famille des NLR contenant un domaine pyrine , Protéines de liaison aux phosphates , Pyroptose , Transduction du signal , Animaux , Lipocaline-2/métabolisme , Lipocaline-2/génétique , Protéine-3 de la famille des NLR contenant un domaine pyrine/métabolisme , Protéine-3 de la famille des NLR contenant un domaine pyrine/génétique , Humains , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Facteur de transcription NF-kappa B/métabolisme , Souris , Muqueuse intestinale/métabolisme , Muqueuse intestinale/anatomopathologie , Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Souris knockout , Rectocolite hémorragique/métabolisme , Rectocolite hémorragique/anatomopathologie , Rectocolite hémorragique/génétique , Rectocolite hémorragique/induit chimiquement , Mâle , Souris de lignée C57BL , Cellules épithéliales/métabolisme , Cellules épithéliales/anatomopathologie , Inflammation/métabolisme , Inflammation/anatomopathologie , Inflammation/génétique , Colite/métabolisme , Colite/anatomopathologie , Colite/induit chimiquement , Colite/génétique , Femelle , GasderminesRÉSUMÉ
Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers. Chemotherapy remains one dominant therapeutic strategy, while a substantial proportion of patients may develop chemotherapeutic resistance; therefore, it is particularly significant to identify the patients who could achieve maximum benefits from chemotherapy. Presently, four pyroptosis genes are reported to correlate with the chemotherapeutic response or prognosis of HNSCC, while no study has assessed the combinatorial predicting efficacy of these four genes. Hence, this study aims to evaluate the predictive value of a multi-gene pyroptosis model regarding the prognosis and chemotherapeutic responsiveness in HNSCC. Methods: By utilizing RNA-sequencing data from The Cancer Genome Atlas database and the Gene Expression Omnibus database, the pyroptosis-related gene score (PRGscore) was computed for each HNSCC sample by performing a Gene Set Variation Analysis (GSVA) based on four genes (Caspase-1, Caspase-3, Gasdermin D, Gasdermin E). The prognostic significance of the PRGscore was assessed through Cox regression and Kaplan-Meier survival analyses. Additionally, chemotherapy sensitivity stratified by high and low PRGscore was examined to determine the potential association between pyroptosis activity and chemosensitivity. Furthermore, chemotherapy sensitivity assays were conducted in HNSCC cell lines in vitro. Results: As a result, our study successfully formulated a PRGscore reflective of pyroptotic activity in HNSCC. Higher PRGscore correlates with worse prognosis. However, patients with higher PRGscore were remarkably more responsive to chemotherapy. In agreement, chemotherapy sensitivity tests on HNSCC cell lines indicated a positive association between overall pyroptosis levels and chemosensitivity to cisplatin and 5-fluorouracil; in addition, patients with higher PRGscore may benefit from the immunotherapy. Overall, our study suggests that HNSCC patients with higher PRGscore, though may have a less favorable prognosis, chemotherapy and immunotherapy may exhibit better benefits in this population.
Sujet(s)
Tumeurs de la tête et du cou , Pyroptose , Carcinome épidermoïde de la tête et du cou , Humains , Pyroptose/effets des médicaments et des substances chimiques , Pyroptose/génétique , Carcinome épidermoïde de la tête et du cou/génétique , Carcinome épidermoïde de la tête et du cou/traitement médicamenteux , Carcinome épidermoïde de la tête et du cou/mortalité , Carcinome épidermoïde de la tête et du cou/anatomopathologie , Pronostic , Tumeurs de la tête et du cou/génétique , Tumeurs de la tête et du cou/traitement médicamenteux , Tumeurs de la tête et du cou/anatomopathologie , Caspase-1/génétique , Caspase-1/métabolisme , Mâle , Femelle , Caspase-3/génétique , Caspase-3/métabolisme , Protéines de liaison aux phosphates/génétique , Protéines de liaison aux phosphates/métabolisme , Résistance aux médicaments antinéoplasiques/génétique , Adulte d'âge moyen , Cisplatine/pharmacologie , Cisplatine/usage thérapeutique , Régulation de l'expression des gènes tumoraux , Antinéoplasiques/usage thérapeutique , Antinéoplasiques/pharmacologie , Estimation de Kaplan-Meier , Fluorouracil/pharmacologie , Fluorouracil/usage thérapeutique , Sujet âgé , GasderminesRÉSUMÉ
In the meiotic prophase, programmed DNA double-strand breaks are repaired by meiotic recombination. Recombination-defective meiocytes are eliminated to preserve genome integrity in gametes. BRCA1 is a critical protein in somatic homologous recombination, but studies have suggested that BRCA1 is dispensable for meiotic recombination. Here we show that BRCA1 is essential for meiotic recombination. Interestingly, BRCA1 also has a function in eliminating recombination-defective oocytes. Brca1 knockout (KO) rescues the survival of Dmc1 KO oocytes far more efficiently than removing CHK2, a vital component of the DNA damage checkpoint in oocytes. Mechanistically, BRCA1 activates chromosome asynapsis checkpoint by promoting ATR activity at unsynapsed chromosome axes in Dmc1 KO oocytes. Moreover, Brca1 KO also rescues the survival of asynaptic Spo11 KO oocytes. Collectively, our study not only unveils an unappreciated role of chromosome asynapsis in eliminating recombination-defective oocytes but also reveals the dual functions of BRCA1 in safeguarding oocyte genome integrity.
Sujet(s)
Protéine BRCA1 , Protéines du cycle cellulaire , Souris knockout , Ovocytes , Ovocytes/métabolisme , Animaux , Protéine BRCA1/génétique , Protéine BRCA1/métabolisme , Femelle , Souris , Protéines du cycle cellulaire/métabolisme , Protéines du cycle cellulaire/génétique , Méiose/génétique , Protéines mutées dans l'ataxie-télangiectasie/génétique , Protéines mutées dans l'ataxie-télangiectasie/métabolisme , Protéines mutées dans l'ataxie-télangiectasie/déficit , Cassures double-brin de l'ADN , Appariement des chromosomes/génétique , Endodeoxyribonucleases/métabolisme , Endodeoxyribonucleases/génétique , Checkpoint kinase 2/génétique , Checkpoint kinase 2/métabolisme , Protéines de liaison aux phosphates/métabolisme , Protéines de liaison aux phosphates/génétique , Recombinaison génétique , Recombinaison homologue , Instabilité du génomeRÉSUMÉ
BACKGROUND: Macrophages play a crucial role in atherosclerotic plaque formation, and the death of macrophages is a vital factor in determining the fate of atherosclerosis. GSDMD (gasdermin D)-mediated pyroptosis is a programmed cell death, characterized by membrane pore formation and inflammatory factor release. METHODS: ApoE-/- and Gsdmd-/- ApoE-/- mice, bone marrow transplantation, and AAV (adeno-associated virus serotype 9)-F4/80-shGSDMD (shRNA-GSDMD) were used to examine the effect of macrophage-derived GSDMD on atherosclerosis. Single-cell RNA sequencing was used to investigate the changing profile of different cellular components and the cellular localization of GSDMD during atherosclerosis. RESULTS: First, we found that GSDMD is activated in human and mouse atherosclerotic plaques and Gsdmd-/- attenuates the atherosclerotic lesion area in high-fat diet-fed ApoE-/- mice. We performed single-cell RNA sequencing of ApoE-/- and Gsdmd-/- ApoE-/- mouse aortas and showed that GSDMD is principally expressed in atherosclerotic macrophages. Using bone marrow transplantation and AAV-F4/80-shGSDMD, we identified the potential role of macrophage-derived GSDMD in aortic pyroptosis and atherosclerotic injuries in vivo. Mechanistically, GSDMD contributes to mitochondrial perforation and mitochondrial DNA leakage and subsequently activates the STING (stimulator of interferon gene)-IRF3 (interferon regulatory factor 3)/NF-κB (nuclear factor kappa B) axis. Meanwhile, GSDMD regulates the STING pathway activation and macrophage migration via cytokine secretion. Inhibition of GSDMD with GSDMD-specific inhibitor GI-Y1 (GSDMD inhibitor Y1) can effectively alleviate the progression of atherosclerosis. CONCLUSIONS: Our study has provided a novel macrophage-derived GSDMD mechanism in the promotion of atherosclerosis and demonstrated that GSDMD can be a potential therapeutic target for atherosclerosis.